ERBB2 and gastric cancer: Successful treatment outcomes have been reported in patients with MSI-H gastric cancer, HER2-amplified gastric cancer, STK11-mutant NSCLC, PD-1-resistant nasopharyngeal carcinoma, multiple primary malignancies, and super-aged populations.